Myoma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 18, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Myoma. It connects disease background, epidemiology, a target-mechanism anchor, clinical competition, transaction activity, unmet need and market attractiveness for portfolio and business-development decisions.

Executive assessment

Myoma receives a directional strategic score of 61/100. The synthesis combines unmet need (75/100), competitive intensity (88/100, where a higher value means more competition) and market attractiveness (79/100). It is an evidence-organizing framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A benign neoplasm of muscular tissue. (Stedman, 25th ed)

The reproducible entity is Patsnap disease ID c046d673066f4a7c8a5782f5279e6aa3 with MeSH identifier D009214. Entity-level identifiers matter because rare disorders often carry historical names, gene-defined subtypes and overlapping clinical labels. Strategy teams should lock the intended label and synonym set before comparing epidemiology, trials and deals.

A useful target product profile must specify the treatable phenotype, age and severity range, diagnostic confirmation, prior-therapy requirements, treatment setting, acceptable safety profile and endpoint. In Myoma, an overly broad label can inflate the theoretical market while diluting biological signal and making recruitment less predictable.

The care pathway should be mapped from symptom recognition through specialist referral, molecular or biochemical confirmation, treatment initiation and longitudinal monitoring. Diagnostic delay, fragmented referral and limited centers may be as important commercially as drug efficacy. These barriers should appear explicitly in launch and evidence-generation plans.

Epidemiology and disease burden

Epidemiology signal 1: CCDC Weekly Reports (Vol. 8 No. 10 Mar. 6, 2026) Shifting Patterns of Anemia Prevalence and Severity AmongUrban Women — China, 2019–2024

2030). 2017. http://www.gov.cn/zhengce/content/2017-07/13/ content_5210134.htm. (In Chinese). [2026-1-5] Dreisler E, Frandsen CS, Ulrich L. Perimenopausal abnormal uterine bleeding. Maturitas 2024;184:107944. https://doi-org.sutd.idm.oclc.org/10.1016/j. maturitas.2024.107944. 10. Wilson LF, Moss KM, Doust J, Farquhar CM, Mishra GD. First Australian estimates of incidence and prevalence of uterine fibroids: a data linkage cohort study 2000-2022. Hum Reprod 2024;39(9):2134 − 43. https://doi-org.sutd.idm.oclc.org/10.1093/humrep/deae162. 11. Wilson L, Copp T, Hickey M, Jenkinson B, Jordan SJ, Thompson R, et al. Women who experience heavy menstrual bleeding: prevalence and characteristics from young adulthood to midlife, Australia, 2000-2021: a longitudinal cohort survey study. Med J Aust 2025;222(4):191 − 7. https://doi-org.sutd.idm.oclc.org/10.5694/mja2.52596. 12. Park JY, Lee SW. A history of repetitive cesarean section is a risk factor of anemia in healthy perimenopausal women: The Korea National Health and Nutrition Examination Survey 2010-2012. PLoS One 2017;12(11):e0188903. https://doi-org.sutd.idm.oclc.org/10.1371/journal.pone. 0188903. 13. Hassen AE, Agegnehu AF, Admass BA, Temesgen MM. Preoperative anemia and associated factors in women undergoing cesarean section at a comprehensive specialized referral hospital in Ethiopia. Front Med 2023;10:1056001. https://doi-org.sutd.idm.oclc.org/10.3389/fmed.2023.1056001. 14.

Review the underlying epidemiology source

Epidemiology signal 2: Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022

Background: Breast cancer is ranked among the most prevalent malignancies in the Chinese female population. However, compre­ hensive reports detailing the latest epidemiological data and attributable disease burden have not been extensively documented. Methods: In 2018, high-quality cancer surveillance data were recorded in 700 population-based cancer registries in China. We extracted data on female breast cancers (International Classification of Diseases, Tenth Revision [ICD-10]: C50) and estimated the incidence and mortality in 2022 according to the baseline data and corresponding trends from 2010 to 2018. Pathological types were classified according to the ICD for Oncology, 3rd Edition codes. Disability-adjusted life years (DALYs) were calculated as the sum of the years of life lost (YLLs) and years lived with disability (YLDs). l 2022 i l 3 200 f l b d 000 d h d i Chi i f

Review the underlying epidemiology source

Epidemiology signal 3: 中国女性乳腺癌疾病负担与经济负担:系统整合分析 Disease burden and economic burden of breast cancer in females in China: a synthesis analysis

结 果 1. 资料基本信息：6 个数据源基本信息见表1。 鉴于前期研究对于部分数据源已有介绍 ［3］，本文仅 展示2016年后有更新的数据源。 表1 本研究纳入6个数据源的基本信息 注：CI5：五大洲癌症发病率；GBD：全球疾病负担研究；IARC：国际癌症研究署；DALY：伤残调整寿命年； a本研究报道的上海市女性乳腺癌 发病率参考CI5数据库中CI5plus数据 2. 疾病负担现况：GLOBOCAN 2022 估计 2022 年中国女性乳腺癌发病世标率、死亡世标率 和1 年患病世标率分别为33.0/10 万、6.1/10 万和 40.1/10万。GBD 显示2021年中国女性乳腺癌发病 世标率、死亡世标率和时点患病世标率分别为 37.0/10万、8.2/10万和355.7/10万。 《中国肿瘤登记年 报》显示，2018 年中国肿瘤登记地区女性乳腺癌发 病世标率与死亡世标率分别为28.4/10万和5.8/10万； 城乡发病比为1.4∶1，死亡比为1.2∶1。 《中国死因监 测数据集》显示，2021 年中国女性乳腺癌死亡世标 率为4.5/10 万，城乡死亡比为1.2∶1。见表2。中国 女性乳腺癌发病率随年龄增加先上升后下降，60~ 69 岁出现最高峰值，死亡率随着年龄增加而逐渐 上升，不同数据源之间略有差异，但整体趋势一致 （图1A，B）。

Review the underlying epidemiology source

Epidemiology should be converted into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence are not interchangeable; estimates from different age bands, case definitions or health systems should not be pooled without adjustment.

For Myoma, the next population work should quantify diagnostic yield, severity distribution, referral-center concentration, treatment penetration and survival or progression. Sensitivity analyses should show how each assumption affects recruitment, peak penetration and budget impact. A transparent range is more useful than a single precise-looking estimate built from incompatible sources.

Unmet need and patient-value thesis

The unmet-need thesis must name the failure that a new intervention will change: irreversible progression, incomplete disease control, treatment-limiting toxicity, burdensome administration, weak durability, delayed diagnosis or lack of options for a biomarker-defined subgroup. High disease severity alone does not prove that a clinical program can demonstrate benefit.

A strong Myoma strategy connects mechanism to a pre-specified responder population and an endpoint understood by regulators, clinicians, patients and payers. It also tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Patient-reported outcomes, functional measures and health-resource use may add value when standard biomarkers do not capture daily burden.

The recommended first development population is the narrowest segment that remains operationally recruitable and has the clearest biological rationale. Expansion should follow evidence of target engagement and response rather than precede it. This sequencing protects capital and improves the interpretability of early clinical results.

Target mechanism anchor: PTH1R

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760).

The mechanism anchor for this landscape is PTH1R. It is a pathway hypothesis, not an assertion that every patient is target-dependent. Translational diligence should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream pathway modulation and a therapeutic window in the intended population.

Critical experiments include orthogonal engagement assays, dose–response work in disease-relevant systems, biomarker qualification, evaluation of compensatory pathways and explicit on-target and off-target safety testing. Human evidence should receive more weight than model-only findings. Negative results in related mechanisms should be analyzed for exposure, population, endpoint and biological lessons.

A go decision requires a chain of evidence: target present in the relevant tissue; modulation achieved at tolerated exposure; pharmacodynamic change observed; and that change plausibly connected to clinical benefit. If any link is missing, the program should remain at a lower investment gate.

Clinical development and competition

The focused query returned 155 registered studies overall. Recent sampled records include:

• NCT07664176 — NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors; status Not yet recruiting; phase Phase 1; sponsor Children's National Research Institute; enrollment 30.
• NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors (VBS-CSI-PT-PED); status Not yet recruiting; phase Not Applicable; sponsor Ruijin Hospital; enrollment 38.
• NCT07584499 — Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors (MRG003); status Recruiting; phase Phase 1; sponsor Sun Yat-Sen University; enrollment 51.

Trial count is not equivalent to the number of competing products. Observational studies, natural-history cohorts and multiple trials from one asset can distort the headline. Each record should be normalized by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy must compare against the likely standard of care at launch, not only today's treatment. Potential whitespace may come from earlier intervention, genotype selection, improved durability, reduced monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim should be visible in protocol design and prospectively defined analyses.

Recruitment risk deserves its own workstream in Myoma. Site density, diagnostic testing, competing protocols, travel burden and screen-failure rates should inform country and center selection. Natural-history data can reduce uncertainty but should not substitute for a well-controlled efficacy strategy when endpoints are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This negative signal can mean limited partnering momentum, a broader deal label or asset-level transactions not indexed to the exact indication. Target- and asset-based comparable searches should be added before valuation.

Headline deal value is rarely a clean comparable. Upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope must be separated. A defensible comparable set matches indication, target, modality, stage and territory, then explains every remaining difference.

Partner readiness depends on a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that can retire a material portion of risk.

For Myoma, direct transaction scarcity can create whitespace, but it can also signal weak validation or a difficult commercial model. Broader pathway deals are useful only when their scientific and economic relevance is made explicit. Avoid treating unrelated rare-disease transactions as interchangeable simply because both populations are small.

Market attractiveness and access

Market attractiveness is shaped by diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, current alternatives, monitoring burden and geographic reimbursement. A rare population can still be attractive when identification is reliable, centers are concentrated and effect size is meaningful; a larger population can disappoint when diagnosis and access are fragmented.

The commercial model should include conservative, base and upside scenarios. Key variables are diagnosed prevalence, eligible share, launch timing, competing approvals, net price, persistence and achievable penetration. Each assumption should have a source, date and range. Scenario outputs should be updated when new epidemiology, trial or transaction evidence arrives.

Payer research should begin before pivotal design so comparator, endpoint and follow-up choices support reimbursement as well as approval. Evidence plans may need quality-of-life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The strongest value proposition ties clinical benefit to outcomes that matter across stakeholders.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate that PTH1R is relevant in the selected phenotype.
• Translation risk: connect engagement to a biomarker and clinically meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing capacity and screen-failure assumptions.
• Commercial risk: test access, pricing and adoption with clinicians and payers.
• Data risk: interpret zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are: confirm population and natural history; validate mechanism in human evidence; define a differentiated target product profile; establish early proof of mechanism; and scale only after clinical signal, operational feasibility and commercial logic converge. Every gate needs pre-agreed stop criteria.

Strategic recommendation

Myoma merits continued, milestone-based evaluation. The opportunity is strongest if a biomarker or phenotype can identify patients with coherent biology, if PTH1R modulation is measurable, and if the proposed benefit is meaningful against future care. The current evidence supports further diligence rather than an unconditional investment decision.

The near-term business-development objective is to build a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard provides a common language for comparison, while the attached evidence and explicit gaps preserve analytical traceability.

Methodology and source note

This report was assembled on August 18, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update. Counts are directional search outputs, not clinical, regulatory or investment advice.

Ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Before a transaction or portfolio commitment, rerun searches with synonyms, disease roll-ups, gene or pathway names and asset filters.

Conclusion

The central question for Myoma is whether a biologically grounded therapy can produce a material patient benefit in an identifiable population and remain differentiated through launch. The current evidence supplies a structured starting point; the gaps define the next diligence plan. Connected MCP searches make the thesis refreshable as disease knowledge, trials and transactions evolve.